Verification evidence is still being completed.
PDF / print export
IO Biotech
Copenhagen, Denmark
- Verified lead
- Mai-Britt Zocca
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Immuno-Oncology, Cancer Therapeutics, Immune-Modulating Vaccines, and Clinical Development
- Review cycle
- May 2026
- Full address
- Ole Maaloes Vej 3, 2200 Copenhagen N, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official IO Biotech contact page confirming the Copenhagen address.
- Editorial note
- IO Biotech is published because the official site confirms current executive leadership, Copenhagen operating address, and a clear clinical-stage immuno-oncology platform.
Immuno-Oncology, Cancer Therapeutics, Immune-Modulating Vaccines, and Clinical Development
Official leadership disclosure, Official Copenhagen contact disclosure, Clinical-stage therapeutics platform claim
IO Biotech is published because the official site confirms current executive leadership, Copenhagen operating address, and a clear clinical-stage immuno-oncology platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Copenhagen, Denmark
IO Biotech
Immuno-Oncology, Cancer Therapeutics, Immune-Modulating Vaccines, and Clinical Development · Clinical-stage therapeutics platform
IO Biotech runs immuno-oncology development, clinical therapeutics programs, and cancer vaccine platform in Copenhagen, Denmark.
- Lead
- Mai-Britt Zocca (verified ↗)
- Address
- Ole Maaloes Vej 3, 2200 Copenhagen N, Denmark (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Immuno-Oncology Development · Clinical Therapeutics Programs · Cancer Vaccine Platform
- Founded
- 2014
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Mai-Britt Zocca
CEO
Full addressOle Maaloes Vej 3, 2200 Copenhagen N, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official IO Biotech contact page listing the Ole Maaloes Vej 3 Copenhagen address.
Open sourceClinical-stage therapeutics platform
Copenhagen, Denmark. Immuno-Oncology, Cancer Therapeutics, Immune-Modulating Vaccines, and Clinical Development. Review completed on 21 Mar 2026.
Danish corporate and clinical-development oversight
Official leadership disclosure, Official Copenhagen contact disclosure, Clinical-stage therapeutics platform claim
Immuno-Oncology, Cancer Therapeutics, Immune-Modulating Vaccines, and Clinical Development
IO Biotech is published because the official site confirms current executive leadership, Copenhagen operating address, and a clear clinical-stage immuno-oncology platform.
Editorial note
IO Biotech is published because the official site confirms current executive leadership, Copenhagen operating address, and a clear clinical-stage immuno-oncology platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Immuno-Oncology Development
Clinical Therapeutics Programs
Cancer Vaccine Platform
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Immunotherapy R&D platform
Translational oncology systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is IO Biotech located?
- IO Biotech operates from Ole Maaloes Vej 3, 2200 Copenhagen N, Denmark, Copenhagen, Denmark.
- Who runs IO Biotech?
- IO Biotech is led by Mai-Britt Zocca, CEO. Verified 21 Mar 2026.
- What does IO Biotech do?
- IO Biotech runs immuno-oncology development, clinical therapeutics programs, and cancer vaccine platform in Copenhagen, Denmark. Core capabilities: Immuno-Oncology Development, Clinical Therapeutics Programs, Cancer Vaccine Platform.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.